Raltegravir in Virologically Suppressed Overweight WomenRaltegravir in Virologically Suppressed Overweight Women
When women with central adiposity switch to RAL from a PI or NNRTI, they could experience a significant decrease in sCD14. HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 25, 2014 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news
Could HIV drugs help treat multiple sclerosis?
Conclusion
This large cohort study indicates people with HIV appear to be at a lower risk of developing MS. It is not known what causes this association, but possible reasons put forward by the researchers include:
immunodeficiency caused by HIV may stop the body attacking itself in the autoimmune condition MS
antiretroviral therapy may suppress other viruses in the body, such as those that have been suggested as causing MS
Strengths of the study include the large sample size and the very large number of controls, which would limit any bias by confounding factors.
However, the study did have a few limitations:
...
Source: NHS News Feed - August 5, 2014 Category: Consumer Health News Tags: Medication Neurology Source Type: news
Raltegravir Not Better Than NRTIs for Refractory HIVRaltegravir Not Better Than NRTIs for Refractory HIV
Raltegravir showed no benefits over nucleoside reverse-transcriptase inhibitors when used in combination with a protease inhibitor as second-line HIV therapy. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2014 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine
Dateline City:
WHITEHOUSE STATION, N.J.
If Approved, Fixed-Dose Combination Would Be Used with Other Antiretroviral Agents for the Treatment of HIV-1 in Adults, Adolescents and Certain Pediatric Patients
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for a fixed-dose combination (FDC) of raltegravir with lamivudine for the treatment of HIV-1 infection (MK-0518B) has been accepted for standard review by the U.S. Food and Drug Administrati...
Source: Merck.com - Research and Development News - June 24, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)
Dateline City:
WHITEHOUSE STATION, N.J.
ONCEMRK Study Globally Enrolling Treatment-Naïve Adults with HIV-1
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the first patient has been enrolled in the
company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a
once-daily investigational formulation of ISENTRESS®
(raltegravir), known as reformulated raltegravir, as part of co...
Source: Merck.com - Research and Development News - June 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Human endogenous retrovirus (HERV) research
A pilot study of an anti-human endogenous retrovirus antibody suggests it is safe and has some effect on MS (no progression in 7 people over 12 months). Another related study being into an anti-HIV drug called raltegravir (Isentress) is expected to report by the end of the year.
MedPage Today
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 29, 2014 Category: Neurology Source Type: news
Merck Announces First-Quarter 2014 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
First-Quarter 2014 Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $0.57; Confirms 2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47
Worldwide Sales were $10.3 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Unfavorable Impact from Foreign Exchange
Strategic Initiatives Drove Cost R...
Source: Merck.com - Financial News - April 29, 2014 Category: Pharmaceuticals Tags: Financial News Latest News Source Type: news
FDA Updates Raltegravir (Isentress) Labeling
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir.
“In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of telaprevir or boceprevir. No dose adjustment is required for Isentress or boceprevir or telaprevir.”
The revised label is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Raltegravir (Isentress) patient fact sheet (Source: AIDSinfo At-a-Glance: Offering Information on HIV/A...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news
3 Regimens Hold HIV in Check Without Efavirenz
BOSTON (MedPage Today) -- Three different regimens for treating HIV patients -- one using the twice daily integrase inhibitor raltegravir (Isentress) and two based with ritonavir-boosted protease inhibitors -- effectively suppressed the virus, researchers said here. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 8, 2014 Category: Gastroenterology Source Type: news
Raltegravir Combo Gives New Anti-HIV Alternative
BOSTON (MedPage Today) -- The use of a two-drug anti-HIV therapy of raltegravir (Isentress) plus darunavir (Prezista) appeared to be non-inferior to tenofovir/emtricitabine (Truvada) plus darunavir, researchers reported here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - March 6, 2014 Category: Consumer Health News Source Type: news
New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Dateline City:
BOSTON
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
said today that in a new 96-week, open-label AIDS Clinical Trials Group
(ACTG) study designed to compare three different NNRTI-sparing HIV
regimens in treatment-naïve patients – one containing Merck’s
twice-daily ISENTRESS® (raltegravir) and two containing
different once-daily ritonavir-boosted protease inhibitors, atazanavir
and darunavir -- all three regimens achieved high and equivalent levels
of...
Source: Merck.com - Research and Development News - March 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news
New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Dateline City:
BOSTON
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
said today that in a new 96-week, open-label AIDS Clinical Trials Group
(ACTG) study designed to compare three different NNRTI-sparing HIV
regimens in treatment-naïve patients – one containing Merck’s
twice-daily ISENTRESS® (raltegravir) and two containing
different once-daily ritonavir-boosted protease inhibitors, atazanavir
and darunavir -- all three regimens achieved high and equivalent levels
of ...
Source: Merck.com - Product News - March 5, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Cipla to market MSD's HIV drug 'raltegravir' in India
MSD in India Managing Director K G Ananthakrishnan said the partnership is aligned with the company's commitment towards patients in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 20, 2014 Category: Pharmaceuticals Source Type: news
Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
Fourth-Quarter 2013 Non-GAAP EPS Increased by 6 Percent Over Prior Year to $0.88, Excluding Certain Items; GAAP EPS Decreased by 13 Percent to $0.26. Full-Year 2013 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $1.47.
Fourth-Quarter 2013 Worldwide Sales Were $11.3 Billion, a Decrease of 4 Percent Reflecting Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange.
...
Source: Merck.com - Corporate News - February 5, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
FDA Clears New Formulation of Raltegravir for Infants FDA Clears New Formulation of Raltegravir for Infants
The oral suspension formulation of the HIV integrase inhibitor may be used in patients as young as 4 weeks of age. FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 11, 2014 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news
